who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

ZTS · Q2 2026

Archived report (Q2 2026). Latest deep dive →

US GAAP, Q2 2026 · quarter ended 06/30/2026 · released Aug 6

Net income attributable to Zoetis Inc.

$691M

down 4.8% y/y

Revenue

$2,468M

down 0.2% y/y

Operating income (calculated)

$922M

down 4.7% y/y

The quarter in brief

Revenue fell 0.2% y⁠/⁠y to $2.47B, operating margin 37.4% vs 39.1%, net income $691M (−4.8% y⁠/⁠y).

All figures in $M.

Sankey diagram of ZTS earnings report for Q2 2026: revenue, costs and profitRevenue$2,468 · −0.2%Cost of sales$673 · +1.4%Selling, generalandadministrativeexpenses$592 · −3.6%Research anddevelopmentexpenses$173 · +4.2%Amortization ofintangible assets$31 · −6.1%Restructuringcharges andcertainacquisition anddivestiture-related costs$77 · +157%Operating income(calculated)$922 · −4.7%37.4% marginInterest expense,net ofcapitalizedinterest$61 · +15.1%Other(income)/deductions–net$5 · vs −$2Income beforeprovision fortaxes on income$866 · −5.0%Provision for taxes onincome$175 · −5.9%20.2% effective rateNet income attributable toZoetis Inc.$691 · −4.8%$1.65/sh · 28.0% margin
Sankey diagram of ZTS earnings report for Q2 2026: revenue, costs and profit
Line itemAmount and change
Revenue$2,468 · −0.2%
Cost of sales$673 · +1.4%
Selling, general and administrative expenses$592 · −3.6%
Research and development expenses$173 · +4.2%
Amortization of intangible assets$31 · −6.1%
Restructuring charges and certain acquisition and divestiture-related costs$77 · +157%
Operating income (calculated)$922 · −4.7% · 37.4% margin
Interest expense, net of capitalized interest$61 · +15.1%
Other (income)/deductions–net$5 · vs −$2
Income before provision for taxes on income$866 · −5.0%
Provision for taxes on income$175 · −5.9% · 20.2% effective rate
Net income attributable to Zoetis Inc.$691 · −4.8% · $1.65/sh · 28.0% margin

Verdict: revenue fell 0.2% y/y to $2.47B, operating margin 37.4% vs 39.1%, net income $691M (−4.8% y/y).

Guidance for adjusted diluted EPS was revised to $6.15 - $6.25.

Source and notation

Source: Zoetis press release, 8-K EX-99.1 of 08/06/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL. Operating income is calculated (revenue less costs and operating expenses): the release does not report it.

Open as an image: ZTS, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “ZTS Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/zts/q2-2026. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/zts/q2-2026"><img src="https://whoreportstoday.com/t/zts/q2-2026/sankey.png" alt="ZTS Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/zts/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/zts/q2-2026/sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/zts/q2-2026">ZTS Q2 2026 earnings chart (Who Reports Today)</a>

This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

ZTS — an animal health company that discovers, makes and sells medicines, vaccines, diagnostics and genetic tests for pets, horses and livestock, selling mainly to veterinarians and livestock producers in more than 100 countries.

It manages the business through two geographic segments, the United States and International, each covering both companion animal and livestock products. · Source: annual report (Form 10-K, SEC)

More reports: A · Q3 FY2026 · ABBV · Q3 2026 · ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · all reports

Company reports

Q3 2026latest breakdownQ3 2026 revenue was $2,391 million, down 1% from $2,422 million a year earlier, while net income fell 18% to $591…
Q2 2026Revenue fell 0.2% y/y to $2.47B, operating margin 37.4% vs 39.1%, net income $691M (−4.8% y/y).

Cookies the site needs and, with your consent, Google Analytics — privacy policy